The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Posting per waterloo01 from the other board:
https://www.bbc.co.uk/news/health-46973641
The drugs advisory body, the National Institute for Health and Clinical Excellence, and NHS England will also trial a new payment model that means pharmaceutical companies will be paid for drugs based on how valuable the medicines are to the NHS, rather than by the quantity of drugs sold.
Per football from the other board:
Drug firms get millions for war on superbugs
First new class of antibiotics in four decades
https://www.thetimes.co.uk/edition/news/drug-firms-get-millions-for-war-on-superbugs-mm0lkr6p5
Hi Folks - I am looking at the NASDAQ which is currently 8.45% down to $1.30 = £0.20p & for me the longer it takes for the SP to improve gives me more time to find funds in order to Buy more shares so to average down.However will this share ever recover for me it needs to get to £1.00 5x where we are now?
Doctors need to double the dose of antibiotics they give to patients with gonorrhoea because it's becoming resistant to medicine, experts have warned.
The British Association for Sexual Health and HIV (BASHH) today issued new guidelines for treating the STI for the first time since 2011.
Its recommendations follow news released earlier this month that two women in the UK caught 'super gonorrhoea' - one of whom was the first to ever catch it in Britain.
BASHH urges doctors to stop using one of the routine antibiotics and to increase the dose of another in what it called 'a major change'.
Let’s hope for a repeat
In September 2008, Duggan was appointed CEO of Pharmacyclics, a California-based biopharmaceutical company that was founded in 1991. At the time, Pharmacyclics had a market capitalization of $15 million and was on the brink of collapse. Duggan, who was the company’s largest shareholder with 24.1% of the outstanding stock, took on the challenge of turning around the failing firm which he once described in retrospect as a "collision course to disaster." He began accumulating shares in the company in 2004 when the stock traded around $10. From then to mid-2007, the stock fell to as low as $3 per share due to a number of internal issues. Instead of cutting his losses by selling what little value the stock had left, Duggan stuck it through and continued purchasing more shares.
During his tenure from 2008-2015, Duggan saved Pharmacyclics and turned it into a billion-dollar company with more than 500 employees. The turn of events was mainly influenced by a successful drug the company developed called Imbruvica. It was a treatment for chronic lymphocytic leukemia. As a result, Pharmacyclics’ stock price dramatically increased, making Duggan a billionaire by 2014. In 2015, AbbVie announced it would be acquiring Pharmacyclics for $21 billion. Duggan grossed $3.4 billion from the sale.
No was looking at some of AMR conferences/ events in early 2019; to see who speakers were/ what they were talking sbout
Do you have to pay for access to that?
Go to Programme Day 2
13:20 THE DEVELOPMENT OF PRECISION ANTIBIOTICS: AGENTS DESIGNED TO MEET THE DEMANDS OF STEWARDSHIP
David Roblin
David Roblin, President of R&D, Chief Operating Officer and Chief Medical Officer, Summit Theraputics
View Bio
Summit’s development strategy exemplifies good antibiotic stewardship and I will focus on two programmes from our antibiotic pipeline:
• Ridinilazole is a narrow spectrum, new mechanism of action antibiotic for the treatment of C. difficile infection and the reduction of disease recurrence. Ridinilazole’s narrow spectrum of activity is important: it both treats the infection whilst preserving the microbiome from further perturbation and thus reducing recurrences. Summit’s Phase 3 development programme is designed to show ridinilazole has superiority over vancomycin and support its use as a new first line therapy.
• SMT-571 a novel first-in-class oral antibiotic with activity effective against the Gram-negative bacterial pathogen, Neisseria gonorrhoeae, the causative agent of the sexually transmitted infection gonorrhoea. SMT-571 has the potential to satisfy the Target Product Profile (TPP), recommended by the World Health Organization (WHO) and Drugs for Neglected Disease initiative (DNDi) for an oral agent to treat multi-drug resistant gonorrhoea.
https://www.smi-online.co.uk/pharmaceuticals/uk/superbugs-superdrugs#day_2
FYI SUMM presenting
$25m subscription completed..........
Two cases of resistant gonorrhoea diagnosed in the UK
https://www.gov.uk/government/news/two-cases-of-resistant-gonorrhoea-diagnosed-in-the-uk
Your prediction seems to have proved correct, so far. stew200
Thank you Christrdg.
Nice explanation.
Hopefully the price will stay up, because of the extra volume. Even though it wont be on sale, it has a 25p value.
Hi Albino - The shares in question relate to last weeks motions being passed relating to the new investor who has bought a new issue of shares for 25p representing approx 50% of the original SC.These shares will not at this stage be going on to the market as they are the investors own investment in Summit.The SP move this morning reflects the increase on the NASDAQ last night up to $1.85 - £0.29p.I am now showing as a 'Strong Buy'.
Well what ever it means, the Market seems to like it.
I may be reading this wrong, but it looks like a load of new shares tomorrow and the price has gone up today.
This should be flying tomorrow
I like to think of it as someone's New Years Resolution.
Since we've been sat at twenty or below for five weeks.
Without news assume it is just volatility with some pumping and dumping at work.
Time to shoot part mid 20s it would seem
Thanks for the response, Christrdg.
Just a passing interest, the amount I hold makes no difference to anyone.
Hi Albino - With regards the SP the shares will not be going onto the market so SP should not be effected however your share of the company will have halved as has mine.SP should move up when they announce starting Phase 3 C-Diff trials.